Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout

Dow Jones

04/23

By Elias Schisgall

Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.

Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.

Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.

The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.

Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.

Herbster previously led human resources and business operations at Sage Therapeutics.

They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said.

Nathalie Harroy, who currently serves as head of human resources, will also stay with the company.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

April 22, 2026 18:51 ET (22:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2629079968"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629079968\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629079968?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629079968","market":"sh","top_or_hot":-1,"title":"Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-23 06:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVA","symbol_name":"Inventiva S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629079968","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629079968","pubTimestamp":1776898260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.Herbster previously led human resources and business operations at Sage Therapeutics.They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVA":"Inventiva S.A.","BK4139":"生物科技"},"translate_title":"Inventiva在Lanifibranor第三阶段公布之前任命Malkomes为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n\n\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility. \n\n\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene. \n\n\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n\n\n  Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n\n\n  Herbster previously led human resources and business operations at Sage Therapeutics. \n\n\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n\n\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 18:51 ET (22:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}